[{"orgOrder":0,"company":"Nika Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"ITV-1","moa":"Human immunodeficiency virus Glycoprotein 41 (HIV gp41)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nika Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nika Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nika Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nika Pharmaceuticals","sponsor":"Nika Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Vinpocetine","moa":"Phosphodiesterase 1 (PDE1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nika Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nika Pharmaceuticals \/ Nika Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nika Pharmaceuticals \/ Nika Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Nika Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Nika Pharmaceuticals signed a distribution agreement for ITV-1 (ImmunH) in the Republic of Nigeria. ITV-1 is currently being evaluated for the treatment of HIV infections.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          July 18, 2024

                          Lead Product(s) : ITV-1

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The acquisition includes technologies for producing generics as tablet, Vinpocetine, Menthyl Valerate, and Metamizole Sodium, and a dietary supplement, Tribulus Terrestris Herba Extractum Siccum.

                          Product Name : Vinpocetine-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 15, 2024

                          Lead Product(s) : Vinpocetine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank